Glax­it: Flag­ging a loom­ing threat from Gilead and a weak pipeline, Neil Wood­ford is giv­ing up on GSK and pulling out

Af­ter watch­ing Glax­o­SmithK­line grow in­creas­ing­ly ham­pered by a weak pipeline and “stretched” fi­nan­cials, long­time in­vestor Neil Wood­ford has de­cid­ed to quit the phar­ma gi­ant, wor­ried that a ri­val HIV ther­a­py from Gilead may soon crip­ple Vi­iV, the phar­ma gi­ant’s one bright spot.

In a lengthy blog post to­day ti­tled Glax­it, Wood­ford not­ed that he’s been ad­vis­ing the com­pa­ny for years now to split up and do some­thing pos­i­tive for in­vestors. For­mer CEO An­drew Wit­ty, though, re­ject­ed the sug­ges­tions and new CEO Em­ma Walm­s­ley seems set on the same path.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.